Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)
Open Access
- 7 July 2025
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (9) , 1088-1101
Abstract
Background: Family planning is an important aspect of multiple sclerosis (MS), and neuromyelitis optica spectrum disorder (NMOSD) management. Knowledge gaps remain, including optimal perinatal management strategies, and fetal risks associated with disease-modifying therapy (DMT) exposure. Objective: To describe perinatal DMT use, together with pregnancy and neonatal outcomes prospectively recorded in the International MSBase Pregnancy and Women’s Health Registry. Methods: We report summary statistics for data collected between May 2020 and August 2024. Results: A total of 1887 relapsing-remitting MS (RRMS), 12 primary-progressive MS (PPMS), 2 radiologically isolated syndrome (RIS) and 21 NMOSD completed pregnancies were recorded, including 1644 (85.5%) live births, 208 (10.8%) miscarriages, and 6 (0.3%) neonatal deaths. Most women had unassisted (53.8%) or assisted (7.4%) vaginal births. Seventy five percent of pregnancies had DMT exposures within 6 months preconception; 19% of NMOSD, and 62% of MS pregnancies were DMT-exposed during gestation; 18.1% of pregnancies reported in-pregnancy monoclonal antibody DMT exposure. No overt safety signals were seen. Conclusion: This first report from the newly launched MSBase pregnancy registry, establishes an increasing number of pregnancies being conceived on monoclonal antibody therapies. Although no safety signals were observed, it is important to continue monitoring for safety signals in real-world databases as the use of highly effective therapies continues to increase perinatally.Keywords
This publication has 30 references indexed in Scilit:
- Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive reviewAutoimmunity Reviews, 2023
- Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditionsAnnals of Clinical and Translational Neurology, 2023
- The impact of menopause on multiple sclerosisAutoimmunity Reviews, 2023
- Family planning considerations in people with multiple sclerosisThe Lancet Neurology, 2023
- Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum DisorderJAMA Network Open, 2022
- Fetal and post-natal growth in infants of mothers with multiple sclerosis: A case-control studMultiple Sclerosis and Related Disorders, 2022
- Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerationsNature Reviews Neurology, 2020
- Pregnancy and multiple sclerosis: Clinical effects across the lifespanAutoimmunity Reviews, 2019
- Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort studyMultiple Sclerosis and Related Disorders, 2019
- Teratogenicity risk of antiretroviral therapy in pregnancyCurrent HIV/AIDS Reports, 2007